| Title |
Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults
|
|---|---|
| Published by |
ClinicalTrials.gov, April 2020
|
| ClinicalTrials.gov ID |
X Demographics
The data shown below were collected from the profiles of 30,658 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1853 | 6% |
| United States | 1701 | 6% |
| United Kingdom | 1465 | 5% |
| France | 1375 | 4% |
| Canada | 593 | 2% |
| Brazil | 378 | 1% |
| Spain | 269 | <1% |
| Turkey | 241 | <1% |
| Italy | 236 | <1% |
| Other | 2225 | 7% |
| Unknown | 20322 | 66% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 29716 | 97% |
| Scientists | 301 | <1% |
| Practitioners (doctors, other healthcare professionals) | 293 | <1% |
| Science communicators (journalists, bloggers, editors) | 161 | <1% |
| Unknown | 187 | <1% |